Disclaimer: this software uses AI to aggregate and filter content. Please double-check sources before putting info to action.
📰 News Media
- 💉 [Burlington, VT] Major step forward in controversial Overdose Prevention Center proposal - mynbc5.com
- 🚭 [New York City, NY] Senator Schumer urges FDA to crack down on sale of illicit vape and e-cigarette products from China - nydailynews.com
- 💉 [National] US calls for China to execute some of its illegal fentanyl suppliers - nypost.com
- 🛑 [National] One in nine older adults who use cannabis may meet criteria for cannabis use disorder - medicalxpress.com
- 🧠 [International] FDA Hearing on Psychedelics: Concerns, But Overwhelmingly Positive - talkingdrugs.org
🗣️ Social Pulse
Lived/Living Experience
Innovation
- 🤖 New Research: Two decades of prescription opioid-related cardiovascular safety signals: a FAERS-based pharmacovigilance study using machine learning (link) #FrontiersIn #DrugSafetyRegulation - @FrontPharmacol on X
- 🗺️ OVERDOSE PREVENTION I identified the need to look at where overdoses were occurring alongside where naloxone was available. That led to collaboration between the Medical Examiner’s team and Public Health GIS to... - @mremington2023 on X
Opposition Views
📚 Academic Research
- 🔄 Implementation evaluation of a Massachusetts pilot program designed to reduce overdose deaths among Black and Latino men returning from incarceration - Frontiers in Public Health - 2026-09-29 - doi.org
- 🎪 Designing evaluation infrastructure for psychedelic harm reduction at events: a methodological framework with formative mixed-methods field application - Frontiers in Public Health - 2026-09-29 - doi.org
- 🧠 Trauma-informed psychological support alongside long-acting injectable buprenorphine: clients’ perspectives on the Buvidal psychological support service (BPSS) pilot in Wales - Frontiers in Psychiatry - 2026-09-25 - doi.org
⚖️ Law & Policy
- No hits in Law and Policy today.
💸 Funding
Current
- Deadline Approaching🔬 National Institutes of Health - Establishing a Center for the Advancement of Substance Use Disorder (SUD) Pharmacotherapeutics through Training and Preclinical Support (U54 Clinical Trial Not Allowed) - Deadline: Sep 30, 2026
- Deadline Approaching🔬 National Institutes of Health - Limited Competition: Growing Great Ideas: Research Education Course in Entrepreneurship and Product Development for Researchers Studying Drug Use, Drug Misuse, and Drug Addiction (UE5 Clinical Trial Not Allowed) - Deadline: Oct 1, 2026
- 🛠️ Bureau of Justice Assistance - BJA FY 2026 Comprehensive Opioid, Stimulant, and Substance Use Program (COSSUP) Training and Technical Assistance (TTA) - Deadline: Nov 2, 2026
- 🔬 National Institutes of Health - Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional) - Deadline: Jun 16, 2028
- 🔬 National Institutes of Health - Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional) - Deadline: Aug 21, 2028
- 🔬 National Institutes of Health - Avant Garde/Avenir Awards for Investigators Conducting High Risk/High Reward Research on HIV and Substance Use (or Substance Use Disorders) (DP1 Clinical Trial Optional) - Deadline: Sep 25, 2028
- 🔬 National Institutes of Health - HEAL Initiative: Translating Addiction Epidemiology, Prevention, Treatment, and Recovery Research into Practice (R61/R33 - Clinical Trial Optional) - Deadline: Feb 9, 2029
- 🩺 Hearst Foundations - Health - Hearst Foundations (Health) — Year-Round Rolling Application (No Deadlines) - Minimum grant size is $100,000. - Deadline: Year-round, rolling application; there are no deadlines.
- 🗓️ Hearst Foundations - Social Service - Hearst Foundations — Social Service (Year-round, rolling application) - Minimum grant size is $100,000. - Deadline: Year-round, rolling application; there are no deadlines.
- 🧩 Smart Family Fund - Angel Philanthropy (First-Time Grants) - First time grants range from $25,000 to $100,000. - Deadline: Open pitch